Literature DB >> 28564669

Recent Advances in the Treatment of Gliomas - Comprehensive Brain Tumor Center.

Steven A Toms1, Nikolaos Tapinos2.   

Abstract

Gliomas are a class of primary brain tumors arising from the supporting structures of the brain, the astrocytes and oligodendrocytes, which range from benign lesions to its most malignant form, the glioblastoma. Treatment for these lesions includes maximal surgical resection, radiotherapy, and chemotherapy. Recently, novel therapies such as immune modulatory therapies and electrical field treatment of the most malignant form, the glioblastoma, have shown promise in improving survival. We will review recent advances in clinical trials, explore the role of multimodal care in brain tumor therapy, as well as explore advances in molecular biology and nanotechnology which offer new hope for treatment of this class of disease. [Full article available at http://rimed.org/rimedicaljournal-2017-06.asp].

Entities:  

Keywords:  drug delivery; glioblastoma; immunotherapy; nanotechnology; tumor treating fields

Mesh:

Year:  2017        PMID: 28564669

Source DB:  PubMed          Journal:  R I Med J (2013)        ISSN: 0363-7913


  3 in total

1.  Long Non-Coding RNA UBA6-AS1 Promotes the Malignant Properties of Glioblastoma by Competitively Binding to microRNA-760 and Enhancing Homeobox A2 Expression.

Authors:  Feifei Cheng; Jiang Liu; Yundong Zhang; Qiuxiang You; Bo Chen; Jing Cheng; Chunyan Deng
Journal:  Cancer Manag Res       Date:  2021-01-14       Impact factor: 3.989

2.  Analysis of the cytotoxic effects, cellular uptake and cellular distribution of paclitaxel-loaded nanoparticles in glioblastoma cells in vitro.

Authors:  Lin Wang; Chunhui Liu; Feng Qiao; Mingjun Li; Hua Xin; Naifeng Chen; Yan Wu; Junxing Liu
Journal:  Exp Ther Med       Date:  2021-01-27       Impact factor: 2.447

3.  Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling.

Authors:  Eun Ho Kim; Won Seok Lee; Hoon-Kyu Oh
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.